The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..
Keytruda (pembrolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in breast, urothelial, gastric and hepatocellular cancers.
The mid-stage study is evaluating feladilimab – GSK3359609 – plus Merck &Co’s Keytruda (pembrolizumab) compared with placebo plus Keytruda for the potential treatment of patients with PD-L1 positive advanced or ... In addition, GSK has also halted
Although Merck &Co’s rival checkpoint inhibitor Keytruda (pembrolizumab) is dominant in the NSCLC setting, it does not possess similar results in the pre-surgery, neoadjuvant setting. ... With the CheckMate-816 results in hand, Opdivo could gain an
with Merck &Co’s Keytruda (pembrolizumab) in patients with high-risk melanoma and other cancer types.
Keytruda plus chemotherapy also significantly improved overall survival in this trial, reducing the risk of death by 27%. ... The first-line approval for Keytruda gives it an advantage over rival checkpoint inhibitor Opdivo (nivolumab) from Bristol Myers
[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....